Bank of New York Mellon Corp Purchases 31,680 Shares of Vaxcyte, Inc. $PCVX

Bank of New York Mellon Corp boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 7.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 449,694 shares of the company’s stock after acquiring an additional 31,680 shares during the period. Bank of New York Mellon Corp owned 0.35% of Vaxcyte worth $14,620,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. US Bancorp DE boosted its holdings in Vaxcyte by 7.2% in the 1st quarter. US Bancorp DE now owns 5,344 shares of the company’s stock valued at $202,000 after purchasing an additional 357 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Vaxcyte by 1.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,635 shares of the company’s stock worth $1,119,000 after buying an additional 436 shares in the last quarter. KLP Kapitalforvaltning AS boosted its stake in Vaxcyte by 2.2% during the first quarter. KLP Kapitalforvaltning AS now owns 23,000 shares of the company’s stock valued at $868,000 after buying an additional 500 shares during the period. PNC Financial Services Group Inc. grew its position in Vaxcyte by 5.8% during the first quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company’s stock worth $362,000 after buying an additional 524 shares in the last quarter. Finally, Hsbc Holdings PLC increased its stake in Vaxcyte by 3.1% in the 1st quarter. Hsbc Holdings PLC now owns 18,461 shares of the company’s stock worth $675,000 after acquiring an additional 552 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 0.7%

NASDAQ PCVX opened at $48.34 on Tuesday. The company has a 50-day simple moving average of $39.80 and a two-hundred day simple moving average of $35.53. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $94.76. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of -9.99 and a beta of 1.06.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same quarter in the prior year, the firm posted ($0.83) earnings per share. Equities analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PCVX has been the topic of several recent analyst reports. The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research note on Monday, November 10th. Finally, Cowen reissued a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Vaxcyte presently has an average rating of “Moderate Buy” and a consensus target price of $102.00.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.